EP0991626A2

EP0991626A2 - Pyrimidin-2,4,6-trion derivatives, method for producing the same and medicinal products containing these compounds

Info

Publication number: EP0991626A2
Application number: EP98937509A
Authority: EP
Inventors: Frank Grams; Gerd Zimmermann
Original assignee: Roche Diagnostics GmbH
Current assignee: Roche Diagnostics GmbH
Priority date: 1997-06-23
Filing date: 1998-06-19
Publication date: 2000-04-12
Also published as: BR9810286A; CN1268126A; TR199903213T2; AR013119A1; ZA985406B; AU8627898A; CA2294113A1; WO1998058915A3; WO1998058915A2; US6242455B1; KR20010014152A; DE19726427A1; JP2002504917A

Abstract

The invention relates to substances of general formula (I), where R1 and R2, independently of each other, can be H, alkenyl or alkyl, R3 is a W-V group, where W is a bond or a linear or branched alkyl group, which is optionally interrupted by oxygen, sulphur or nitrogen and can be substituted with hydroxy-, amino-, mercapto-, alkoxy-, oxo-, carboxy-, acyl-, alkyl-, aralkyl-, aryl- or heteroaryl groups, and in which V is H, a monocyclic or bicyclic, saturated or unsaturated ring, which can possibly contain between 1 and 4 nitrogen, oxygen or sulphur atoms and can be optionally substituted with hydroxy-, amino-, mercapto-, alkoxy-, oxo-, carboxy-, acyl-, acylamido-, alkyl-, aralkyl-, aryl- or heteroaryl groups; R4 is an -N(R13)-C(O)-R5, -N(R13)-C(O)-OR5, -N(R13)-SO2-R5, -N(R13)-C(S)-R5, -N(R13)-C(S)-OR5, -N(R13)-C(O)-CR14R15(-CR16R17)n -C(O)-R5, or -N(R13)-CR14R15(-CR16R17)n-C(O)-R18 rest, which in each case is linked by the nitrogen atom to the central pyrimidin ring; n is 0 or 1; R13 has the meaning given above for R3 or with R14 or R16 possibly forms a heterocycle having between 4 and 7 members; and R5 is an alkyl-, cycloalkyl-, aralkyl-, aryl- or heteroaryl rest, whereby these rests can be substituted with hydroxy-, amino groups or halogen. R14, R15, R16 and R17, independently of each other, are hydrogen, the C alpha radical of a proteinogenic amino acid, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl, and R14 and R15 or alternatively R16 and R17 can together form a carbocycle having between 3 and 7 members; R18 is OH or N(R6R7), where R6 can be H, alkyl, cycloalkyl, aralkyl, aryl or heteroaryl and R7 is a group which, together with the N atom, represents a proteinogenic or non-proteinogenic alpha or beta amino acid or amino acid amide. In addition, R6 and R7 can together form a ring having between 4 and 7 members, which optionally contains heteroatoms such as oxygen, sulphur or nitrogen and is optionally substituted with alkyl, aralkyl, aryl or heteroaryl. The invention further relates to pharmacologically compatible salts and esters of general formula I and the use of these compounds for manufacturing medicinal products.

Description

Pyrimidine-2,4,6-trione derivatives, processes for their preparation and medicaments containing these compounds

The invention relates to new Pyπmιdm-2,4,6-tπon-Deπvate. their preparation and medicaments containing them. These compounds inhibit metalloproteases, in particular the proteases of the M2, M3 families. Astacin subfamily of M12 and Ml 3 These protease families are in N D Rawlmgs and A J Barret. Methods Enzym (1995) 248, 183-277

In the protease group Ml 2, particular preference is given to BMP-1 as an inhibition target of the compounds of the invention. Further preferred are ECE and NEP from the M13 family and ACE (peptidyl dipeptidase A) from subgroup M2

Metalloproteases play an important role in many physiological and pathophysiological processes. Examples of this are the angiotension converting enzyme (ACE) and the neutral endopeptidase (NEP, EC 3 4 24 1 1), which are involved in the metabolism of a number of blood pressure-regulating peptides (e.g. angiotensin I and ANF (atπal natural factor)) the cleavage of angiotensin I to the blood pressure-increasing angiotensin EI NEP is responsible for the breakdown of the vasodilating peptide ANF. The endothelin converting enzyme (ECE) cleaves the endogenous, inactive big endothelin to the effective vasoconstructor endothelin-1, a peptide consisting of 21 amino acids The inhibition of these enzymes is of great therapeutic importance for the treatment of high blood pressure, heart failure, kidney failure and stroke. BMP-1 (bone morphogenic protein 1) has been recognized as a metalloprotease, which plays a role in the conversion of procollagen into fibular collagen inhibitors of this enzyme are for the treatment of fibrosis and skierotic suitable processes and can also cause scarring during Favorably influence wound healing. (Proc. Natl. Acad. Be USA 93, 5127 (1996), Science Vol. 271, 360 (1996)).

While inhibitors of ACE are already being used therapeutically (e.g. captopril, enalapril, (Exp. Opinion Ther. Patents 6, 1147 (1996)), for the

Metalloproteases such as NEP, ECE have hitherto been known to have no clinically usable active ingredients which are free from undesirable side effects and are available orally.

(Literature reviews: NEP: Pharmacol. Reviews 45, 87 (1993); ECE: Bioorg. Med.

Chem. Lett. 6, 2317 (1996) and publications cited therein on inhibitors of the phosporamidone type. For the BMP-1 there are as yet no low molecular weight ones

Inhibitors known.

It has now been found that the claimed new pyrimidine-2,4,6-trione derivatives show good activity as metalloprotease inhibitors with good oral availability.

The present application therefore relates to substances of the general formula I

in the

Rl and R2 can independently be H, alkenyl or alkyl, R3 represents a group WV in which W represents a bond or a linear or branched alkyl or alkenyl group which can optionally be interrupted by oxygen, sulfur or nitrogen, with hydroxyl, amino, mercapto, alkoxy, oxo, carboxy, Acyl, alkyl, aralkyl, aryl or heteroaryl groups can be substituted and N stands for H, a monocyclic or bicyclic, saturated or unsaturated ring which may optionally contain 1 to 4 nitrogen, oxygen or sulfur atoms and which may be substituted by hydroxy , Amino, mercapto, alkoxy, oxo, carboxy, acyl, acylamido, alkyl aralkyl, aryl or heteroaryl groups can be substituted,

R4 is a radical -Ν (R13) -C (O) -R5, -N (R13) -C (O) -OR5, -N (R13) -SO2-R5, -N (R13) - C (S) - R5, -N (R13) -C (S) -OR5, -N (R13) -C (O) -CR14R15 (-CR16R17) _n -C (O) -R5, or -N (R13) -CR14R15 (- Can be CR16R17) _n -C (O) -R18, which is in each case bound to the central pyrimidine ring via the nitrogen atom, n is 0 or 1

R13 has the meaning given above for R3 or optionally forms a 4 to 7-membered heterocycle with R14 or R16 and

R5 represents an alkyl, cycloalkyl, aralkyl, aryl or heteroaryl radical, which radicals can be substituted by hydroxyl, amino groups or halogen.

R14, R15, R16 and R17 independently of one another represent hydrogen, the Cα residue of a proteinogenic amino acid, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; R14 and R15 or alternatively R16 and R17 together can form a 3 to 7-membered carbocycle. R 1 denotes 8 OH or N (R6R7), where

R6 can be H, alkyl, cycloalkyl, aralkyl, aryl or heteroaryl and R7 stands for a group which together with the N atom represents a proteinogenic or non-proteinogenic α- or β-amino acid or amino acid amide and also R6 and R7 together form one Can form a 4 to 7-membered ring which may contain heteroatoms such as oxygen, sulfur or nitrogen, and may optionally be substituted by alkyl, aralkyl, aryl or heteroaryl.

In addition, pharmacologically acceptable salts and esters of general structure I and the use of these compounds for the production of medicaments.

R1 and R2 are, independently of one another, preferably H or methyl, particularly preferably H

R3 preferably represents H, alkyl, cycloalkyl or aryl, heteroaryl, aralkyl or heteroaralkyl. H or Ci-Cβ-alkyl is particularly preferred

R4 is preferably the residue of a proteinogenic or non-proteinogenic α- or β-amino acid which is linked via the nitrogen atom to the central pyrimidine ring and whose carboxyl group is either free or is connected to Rx or a group -NH-CO-CHR14-CO- Rx, where Rx is hydroxy, alkoxy or the above-described group -N (R6, R7)

R13 is preferably H or alkyl

R14 and R16 are, independently of one another, preferably alkyl or cycloalkyl, or the Cα residue of a proteinogenic amino acid.

R15 and R17 is preferably hydrogen

n is preferably 0.

The combination of the preferred compounds mentioned above is very particularly preferred In all cases, alkyl should be a straight-chain or branched Ci-Cio, preferably Cι-C ₆ ,

Alkyl chain such as Methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, pentyl or

Be hexyl.

An alkenyl group means unsaturated residues with 3-6 C atoms, e.g. Allyl, but-2-enyl, hexa-2,4-dienyl.

Cycloalkyl stands for a 3-7 membered ring in which a CH2 group through O or

NH can be replaced as u. a. the cyclopropyl, cyclobutyl, cyclopentyl,

Cyclohexyl or the cycloheptyl ring, preferably the cyclopentyl and the

Cyclohexyl ring. Alkoxy groups mean a combination of an alkyl group according to the above

Definition, with an oxygen atom, e.g. B. methoxy, ethoxy, propoxy,

Isopropoxy, butoxy and pentoxy groups, where methoxy, ethoxy and isopropoxy

Butoxy are preferred.

Aryl groups denote a carbon-aromatic radical, preferably one having 6-10 carbon atoms, in particular the phenyl or naphthyl group, which can in each case be linked to hydroxy and amino, which can optionally be substituted by alkyl groups, and alkyl and alkoxy groups.

Heteroaryl groups are aromatic radicals which are made up of unsaturated carbon atoms and heteroatoms such as nitrogen, oxygen and sulfur, where the sum of the ring atoms can be between 5 and 10. Examples of this are the

Imidazole, thiazole, triazole, pyridyl, pyrimidyl, pyrazinyl, indolyl and the

Purinyl residue. The imidazolyl, thiazolyl, pyridyl and indolyl radicals are preferred.

Aralkyl groups mean radicals in which an alkyl group defined above is linked to a previously characterized aryl radical, the benzyl radical being preferred.

A heteroaralkyl radical stands for the combination of an alkyl group defined above with an aryl radical described above. Pyridylmethyl is preferred

Imidazolylmethyl and the thiazolylmethyl radical.

Unless otherwise stated, cycloalkyl, aryl and heteroaryl radicals are 1- to 3-fold independently of one another with alkyl, hydroxy, alkoxy, amino, alkylamino,

Dialkylamino, mercapto or thioalkyl substituted. Acyl radicals are straight-chain or branched C ₂ -C 20 carbonyl alkyls, and preference is given to C ₂ -C 6 acyl radicals

If R6 and R7 together with the nitrogen atom to which they are attached form a ring, they are 5-7 rings, preferably a six-membered ring. Particularly preferred are the piperidine, piperazine, tetrahydroquinoline and tetrahydroisoquinoline, bicylo ( 9 4 0) pentadecyl and 1 2.3.4 - tetrahydrobenzo (g) isoquinoline ring.

When R14 and R15 or R16 and R17 form a carbocycle, a 4, 5 or 6 ring is preferred

The monocycle listed under V is understood to mean saturated or unsaturated ring systems with 3 to 8, preferably 5 to 7 carbon atoms, which can optionally be interrupted one or more times by heteroatoms such as nitrogen, oxygen or sulfur, in particular cyclopentyl, cyclohexyl, cycloheptyl -, morpholinyl, thiamorpholinyl, piperidinyl, piperazinyl, tetrahydrofüranyl, tetrahydropyranyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furyl, thiophenyl, imidazolyl, thiazolyl, oxaz Isothiazolyl, isoxazolyl, 1,2,3-triazolyl or 1,2,4-triazolyl radical. Lower alkyl, alkoxy and halogen are particularly suitable as substituents.

The bicycles listed under V are preferably radicals such as naphthyl, tetrahydronaphthyl, decalinyl, quinolinyl, isoquinolin-yl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, indazolyl, benzindolyl, oxindolyl, oxindolyl, oxindolyl -, Benzothiophenyl-, Benzthiazoiyl, Benzoxazolyl- or the Purinylrest, but especially around the Naphthyl-, Quinolinyl-, Isoquinolinyl-, Tetrahydrochinolinyl-, Indolyl-, or Benzimidazolylrest

The following are some examples of non-proteinogenic amino acids: 2-amino-2-methylbutane carboxylic acid, 2-fluoro-ß-alanine, ß-alanine, 2,3-

Diaminosuccinic acid, ß-aminoisobutyrecarboxylic acid, isoserine, 2-amino-3-hydroxy- 4-methylpentanecarboxylic acid, 2-amino-3-methoxybutanecarboxylic acid, diaminopropionic acid, 2-amino-2-methyl-3-hydroxypropanecarboxylic acid, 2-amino-2-methylbutanedicarboxylic acid, 2-amino-3-hydroxy-3-methylbutanecarboxylic acid, 2,3- Diaminopropionic acid, 2-amino-2-methyl-3-hydroxypropanecarboxylic acid, 2-amino-2-methylbutanedicarboxylic acid, 2-amino-2-methyl-4-pentenecarboxylic acid, 2-amino-3-methoxypropanecarboxylic acid, 1-amino-1-cyclohexane carboxylic acid, 1-amino- 1 - cyclopentane carboxylic acid, 1 - aminocyclobutane carboxylic acid, 1 aminocyclopropane carboxylic acid, 2- (2-furyl) glycine, 2-amino-3-fluorobutyric acid, 2-aminoisobutyric acid, 3-chloro-alanine, 3-fluoro-norleucine, 3-fluoro-valine, 3-fluoroalanine, 3-methoxy-valine, α-cyano-alanine, α-methyl-leucine, ß-chloro-alanine, ß-cyano-alanine, ß-hydroxy-leucine, ß-hydroxyaspartic acid, 3-hydroxyaspartic acid, 2-aminobutyric acid, allylglycine, γ-methylleucine, homoserine, norleucine, norvaline, tert-leucine, 2,3-diaminosuccinic acid, 2-amino-4-pentenecarboxylic acid, 2-amine oheptane carboxylic acid, 2-cyclopropyl-2-methylglycine, 4-thiaisoleucine, allothreonine, α-methylaspartic acid, α-methylserine, ß-

Hydroxynorvaline, ß-methylaspartic acid, homocysteine, O-methylserine, penicillamine, propargylglycine, vinylglycine, H-4,5-dehydro-Leu-OH, H-α-Me-Val-OH, H- propargyl-Gly-OH, H- Allo-Ile-OH, H-Pra-OH, H-Trans-4,5-dehydro-Lys-OH, 3-hydroxyaspartic acid, 6-hydroxynorleucine, allo-isoleucine, allyl glycine, α-amino-N-butyric acid, γ -Methylleucine, α, ß-diaminosuccinic acid, O-carbamoyl-serine, S-methyl-cysteine, citrulline, cyclohexylalanine,, y-diaminobutyric acid, aß-diaminopropionic acid, methionine sulfoxide, C-methyl-alanine, N-methyl-glycine ( Sarcosine), naphthylalanine, ornithine, 1, 2,3, 4-tetrahydroisoquinoline-3-carboxylic acid, homocysteine, 4-hydroxy-proline, 5-hydroxy-lysine, aminobutyric acid, pantonin, glucosamic acid, lanthionine, aliine, dopa, kanavanine , /? - lysine, ß -alanine. Like L-amino acids, D-amino acids can also be used.

If compounds of the general formula I contain one or more asymmetric carbon atoms, the optically active compounds of the general formula I are also a subject of the present invention Compounds of the general formula I can be prepared by processes known per se, preferably by

a) Compounds of the general formula II

in which R1, R2 and R3 have the meanings given above and T represents a leaving group such as shark or OSO2R8, where shark is chlorine, bromine or iodine and R8 is an aryl or the methyl radical, with a compound of the general formula III

R6

HN s

R7

(lll)

in which R6 and R7 have the meanings given above, functional

Groups can be protected by conventional protective groups, reacted and, if necessary, converted into pharmacologically acceptable salts,

or b) compounds of the general formula IV

in which R3 has the meanings given above, R9 represents alkoxy and R4 has the meaning described above, with a compound of the general formula V.

in which R 1 and R 2 have the meanings given above, are converted and, if appropriate, are converted into pharmacologically acceptable salts,

or

c) in the event that R4 is bonded to the central pyrimidine ring via a carboxamido, carbamoyl, thiocarbamoyl, ureido, sulfonamido or amino radical,

a compound of the general formula VI

in which Rl, R2 and R3 have the meanings given above, with a compound of the general formula VII or VIII

R1 1 - D - Hal (VII) R1 1 N = zA _(V i ||)

in which R1 represents an optionally substituted alkyl, cycloalkyl, aryl or heteroaryl radical, D = C (O), O-C (O), SO2 or a valence line, halogen = chlorine, bromine or iodine and A represent oxygen or sulfur,

implemented and optionally converted into pharmacologically acceptable salts.

Compounds of the general formula II are known from the literature. For example, Prepare brominated 2,4,6-pyrimidine triones in the 5-position by reacting the corresponding dialkyl bromalonate with urea (e.g. Acta Chim. Acad. Sei. Hung. 107 (2), 139 (1981)). By reacting 2,4,6-pyrimidine trions substituted in the 5-position by R3 with bromine (analogously to J. pr. Chemie 136, 329 (1933) or J. Chem. Soc. 1931. 1870) or sulfuryl chloride (J Chem. Soc. 1938, 1622), the corresponding brominated or chlorinated compounds of the general formula II are obtained.

Amines of the general formula III are commercially available or are generally known from the literature.

Compounds of the general formula IV are prepared according to methods known per se using urea (formula V) (see, for example, J. Med. Chem. K), 1078 (1967) or Helvetica Chim. Acta 34, 459 (1959) or Pharmacie 38 (1), 65 (1983)).

The reactions are usually carried out in an alcohol such as methanol, ethanol or butanol in the presence of the corresponding sodium alcoholate at temperatures between 40 ° C and 100 ° C. Compounds of the general formula IV are known from the literature or can be prepared by processes known from the literature. You can z. B. by weakly acidic hydrolysis of the corresponding bislactimethers (see J. Chem. Soc. Chem. Comm. I, 400 (1990)). Other possibilities of representation are e.g. B. in Farmaco Ed. Be. 31 (7), 478 (1976) or Aust. J. Chem., 23 (6), 1229 (1970).

Compounds of the general formula VI can easily be prepared by reacting an appropriately substituted acetamidomalone ester by process b) and then hydrolytically cleaving the acetyl group (see Can. J. Chem. 42 (3), 605 (1964)).

Carboxylic acid chlorides of the general formula VII are known or can be prepared from the corresponding carboxylic acids by generally known methods. The reaction usually takes place with thionyl chloride, or phosphorus tri- or pentabromide or chloride in inert solvents such as dichloromethane, diethyl ether, dioxane or tetrahydrofuran at temperatures from 0 ° C. to 50 ° C., preferably between 20 ° C. and 40 ° C. .

Chloroformic acid esters of the general formula VII are known from the literature or can be obtained from the corresponding alcohols by reaction with phosgene or diphosgene by generally known methods. The reaction runs in inert solvents such as. As diethyl ether, dichloromethane, dioxane, tetrahydrofuran or toluene at temperatures between -20 ° C and 20 ° C. In the case of phosgene, the reaction in the presence of bases, usually tertiary amines such as. B. triethylamine or pyridine.

Sulfonic acid chlorides of the general formula VII are known or can be prepared analogously to the methods described from the corresponding sulfonic acids by reaction with phosphorus pentachloride or thionyl chloride. The reaction is in usually carried out in inert solvents such as dimethylformamide or without solvents at temperatures of 20 ° C to 180 ° C, preferably at 50 ° C to 100 ° C.

Isocyanates of the general formula VTII are known or can be prepared by methods known from the literature. B reacting corresponding alkyl halides of the general formula R1-Hal with potassium cyanate analogously to Synthesis 1978, 760. Further methods involve the reactions of an acid amide of the general formula R1-CONH2 with oxalyl chloride, the thermal decomposition of an acid azide of the general formula R1-CON3 or the reactions of an amine of the general formula R1-NH2 with phosgene (analogous to Ann Chem 562, 110)

The reaction of carboxylic acid halides, sulfonic acid halides or chloroformic acid esters of the general formula VII with amines of the general formula VI is generally carried out in a solvent such as dichloromethane,

Dimethylformamide or pyridine with the addition of an auxiliary base such as triethylamine or 4-dimethylaminopyridine at a temperature between -10 ° C and 50 ° C, preferably at room temperature

Compounds of the general formula I can contain one or more chiral centers and can then be present in racemic or in optically active form. The racemates can be separated into the enantiomers by methods known per se. The racemic mixtures are preferably reacted with an optically active acid such as eg D- or L-tartaric acid, almond acid, malic acid, lactic acid or camphorsulfonic acid or an optically active amine such as eg D- or L-phenylethylamine, ephedrine, quinidine or cinchonidine, diastereomeric salts which can be separated by crystallization

The pharmacological contractual salts used are primarily alkali metal salts, ammonium salts, acetates or hydrochlorides, which are obtained in a conventional manner, for example by titration of the compounds with inorganic or organic bases or inorganic acids such as. As sodium hydroxide, potassium hydroxide, aqueous ammonia, amines such as. B. triethylamine or hydrochloric acid. The salts are usually cleaned by falling over from water / acetone.

The new substances of the formula I according to the invention and their salts can be administered enterally or parenterally in liquid or solid form. All the usual forms of application are possible here, for example tablets, capsules, dragées, syrups, solutions, suspensions, etc. Water is preferably used as the injection medium, which contains the additives customary for injection solutions, such as stabilizers, solubilizers and buffers.

Such additives are e.g. B. tartrate and citrate buffers, ethanol, complexing agents (such as ethylenediaminetetraacetic acid and its non-toxic salts), high molecular weight polymers (such as liquid polyethylene oxide) for viscosity control. Liquid carriers for injection solutions must be sterile and are preferably filled into ampoules. Solid carriers are e.g. b. Starch, lactose, mannitol, methyl cellulose, talc, highly disperse silicic acids, higher molecular fatty acids (such as stearic acid), gelatin, agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high molecular weight polymers (such as polyethylene glycols); Preparations suitable for oral administration can optionally contain flavorings and sweeteners.

The dosage can depend on various factors, such as the mode of administration, species, age and / or individual condition. The daily doses to be administered are about 10-1000 mg / person, preferably 100-500 mg / person and can be taken in one or more times distributed.

For the purposes of the present invention, preference is given to the compounds which can be derived in addition to the compounds mentioned in the examples and by combining all the meanings of the substituents mentioned in the claims Derivatives of barbituric acid which can be prepared by the processes stated above

1 N- (5-benzyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl) malonic acid 2 N- (5-benzyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl) -malonic acid methyl ester

3 N- (5-benzyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl) -N'-methyl-malonamide

4 3- (2,4,6-Trioxo-hexahydro-pyrimidin-5-ylamino) propionic acid

5 3- (1H-Indol-3-yl) -2- (2,4,6-trioxo-hexahydro-pyrimidin-5-ylamino) propionic acid

6 3- (4-Hydroxyphenyl) -2 - {[1- (2,4,6-trioxo-hexahydro-pyrimidin-5-ylamino) cyclobutane carbonyl] amino} propionic acid

7 l- (2,4,6-trioxo-hexahydro-pyπmιdin-5-yl) -pyrrolidine-2-carboxylic acid

Example 1 N-f2.4,6-Trioxo-5-phenyl-hexahydro-pyrimidin-5-ylVmalonamic acid methyl ester

2 g of 5-amino-5-phenyl-2,4,6-trioxopyrimidine are dissolved in 20 ml of acetonitrile and mixed with 1 5 ml of N-methylmorpholine. While stirring and ice cooling, 1 03 ml of monomethyl malonate are added dropwise and the suspension is stirred at room temperature for 2 hours the precipitate is filtered off with suction, washed with acetonitrile, water and again with acetonitrile and dried. 1 97 g (68%) of the title compound are obtained

TLC Rf = 0 1 (silica gel, isohexane, acetone, glacial acetic acid 7 3 0 1) MS 319 m / e

Example 2

N-Methyl-N '- (2,4,6-trioxo-5-phenyl-hexahvdro-pyrimidin-5-yl-malonamide

160 mg of the compound obtained in Example 1 are added to 7 ml of saturated methanolic methylamine solution. After a short time, the

Crystallization. After 2 hours the suspension is evaporated and the residue is triturated with ether, suction filtered and dried. 149 mg (93%) of the are obtained

Title link.

TLC R _f = 0.3 (silica gel, methylene chloride / methanol 9: 1)

MS 318 m / e

Example 3

3,3-Dimethyl-2- (2.4.6-trioxo-5-phenyl-hexahvdro-pyrimidin-5-ylcarbamov0-butyric acid) ethyl ester

If in Example 1 the monomethyl malonate chloride is replaced by monoethyl t-butylmalonic acid chloride, the title compound is obtained in a yield of 94%.

TLC R _f = 0.62 (silica gel, methylene chloride / methanol 9: 1) MS 389 m / e

Example 4

3.3-Dimethyl-2- (2.4.6-trioxo-5-phenyl-hexahvdro-pyrimidin-5-ylcarbamoyl - butyric acid

1 g of the product obtained in Example 3 is dissolved in ethanol and 0.5 g of potassium hydroxide in 1 ml of water is added. After 2 days at room temperature, the reaction mixture is evaporated, the residue is mixed with ice water and ethyl acetate and acidified to pH 3 with 2N HCl. The ethyl acetate phase is dried and evaporated. 0.7 g (75%) of the title compound are obtained.

TLC R _f = 0.5 (silica gel, methylene chloride / methanol / water 9: 1: 1) MS 361 m / e Example 5

ACE fluorescence assay for IC _S o value determination

Lit .: Arnos Carmel and Arieh Yaron, Eur. J. Biochem. 787: 265-273 (1978). An Intramolecularly Quenched Fluorescent Tripeptide as a Fluorogenic Substrate of Angiotensin-I-Converting Enzyme and of Bacterial Dipeptidyl Carboxypeptidase.

Enzyme: Angiotensin-converting-enzyme from rabbit lung (EC. 3.4.15.1),

Fluka (3.3 U / μg) substrate: Abz-Gly-Phe (NO2) -Pro, M- 1 100 Bachern _J ÄN _S O _? , MG = 483.4 Assay buffer: 0.05 M Tris-HCl O. IM NaCl pH 8.0 excitation: 360 nm (excitation slit: 8 nm)

Emission: 410 nm (emission slit: 10 nm)

Temperature: 36 ° C

Substrate stock solution: 0.4 nM in assay buffer Enzyme stock solution: 50μl / ml assay buffer Inhibitor stock solution: imm in DMSO dil. With assay buffer

Measuring tubes: 50 μl substrate (results in 20 μM) 100 μl enzyme

Make up 0 to 100 μl inhibitor stock solution (0 to 100 μM) the rest to 1 ml.

The substrate, inhibitor and buffer are combined in a temperature-controlled measuring cell, and the enzyme reaction is started by adding enzyme. The increase in fluorescence over time (200 s) is followed in a time.scan. The respective initial speed is determined from the gradient. The ICso value can be determined as follows:

v = v ₀ / (l + [I] / ICso)

v = initial speed

Vo = initial velocity without inhibitor [I] = inhibitor concentration

Table 1 Pharmacological data:

Claims

Expectations

1 compounds of formula I.

O

in the

Rl and R2 can independently be H, alkenyl or alkyl,

R3 represents a group WV, in which W represents a bond or a linear or branched alkyl or alkenyl group which can optionally be interrupted by oxygen, sulfur or nitrogen, with hydroxyl, amino, mercapto, alkoxy, oxo, carboxy, Acyl, alkyl, aralkyl, aryl or

Heteroaryl groups can be substituted and V represents H, a monocyclic or bicyclic, saturated or unsaturated ring, which may optionally contain 1 to 4 nitrogen, oxygen or sulfur atoms and by optionally by hydroxy, amino, mercapto, alkoxy, oxo , Carboxy, acyl, acylamido, alkyl, aralkyl, aryl or heteroaryl groups may be substituted,

R4 a radical -N (R13) -C (O) -R5, -N (R13) -C (O) -OR5, -N (R13) -SO2-R5, -N (R13) - C (S) - R5, -N (R13) -C (S) -OR5, -N (R13) -C (O) -CR14R15 (-CR16R17) „- C (O) -R5, or -N (R13) -CR14R15 (- Can be CR16R17) _n -C (O) -R18, which is in each case bound to the central pyrimidine ring via the nitrogen atom, n is 0 or 1 R13 has the meaning given above for R3 or optionally forms a 4 to 7-membered heterocycle with R14 or R16 and

R5 represents an alkyl, cycloalkyl, aralkyl, aryl or heteroaryl radical, which radicals can be substituted by hydroxyl, amino groups or halogen

R14, R15, R16 and R17 independently of one another are hydrogen, the Cα residue of a proteinogenic amino acid, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, R14 and R15 or alternatively R16 and R17 together can form a 3 to 7-membered carbocycle Rl 8 means OH or N (R6R7), where

R6 can be H, alkyl, cycloalkyl, aralkyl, aryl or heteroaryl and R7 stands for a group which together with the N atom represents a proteinogenic or non-proteinogenic α- or β-amino acid or amino acid amide and also R6 and R7 together form one Can form 4 to 7-membered ring, which optionally contains heteroatoms such as oxygen, sulfur or nitrogen, and can optionally be substituted by alkyl, aralkyl, aryl or heteroaryl

their pharmacologically acceptable salts and esters and their tautomers

Compounds of formula I according to claim 1, wherein R 1 and R ₂ independently of one another are hydrogen or methyl.

Compounds of formula I according to one of claims 1 or 2, where R3 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl

Compounds of formula 1 according to any one of claims 1 to 3, wherein

R4 is preferred the residue of a proteinogenic or non-proteinogenic α or β-amino acid which is linked via the nitrogen atom to the central pyrimidine ring and whose carboxyl group is either present freely or with Rx is connected or a group -NH-CO-CHR13-CO-Rx, where Rx is hydroxyl, alkoxy or the above-described group -N (R6, R7).

5. Medicament containing at least one compound of formula 1 according to one of claims 1-4 together with conventional carriers and auxiliaries.

6. Use of a compound of formula 1 according to any one of claims 1-4 for the manufacture of a medicament for inhibiting the metalloproteases of the families M2, M3, astacin subfamily of Ml 2 and Ml 3.